Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Gemini Space Station Inc (GEMI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Gemini Space Station Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Gemini Space Station Inc trades at $4.29 (market cap $544.29M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 73.3× Gemini Space Station Inc's market cap. Which is the better fit depends on your goals.
| ALNY | GEMI | |
|---|---|---|
Market Cap | $39.89B | $544.29M |
Sector | Health | Technology |
52-Week High | $491.22 | $32.52 |
52-Week Low | $278.09 | $3.91 |
Enterprise Value | $38.15B | $534.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Gemini Space Station (GEMI) trades at $4.31, up 1.41% on the day, but remains in a bearish technical trend with key support at $4. The company reported a net loss of $582.81 million in 2025 on revenue of $179.57 million, with negative profit margins and cash flow from operations. Recent news includes a $100 million investment from Winklevoss Capital but also multiple securities class action lawsuits filed against the company.
The outlook is highly speculative. The capital infusion provides near-term funding, but persistent losses, negative cash flow, and legal challenges present significant risks. Analyst consensus is mixed with a $5.88 price target, suggesting potential upside if the company can execute its turnaround, but the fundamental picture remains weak.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →
